title: Endocannabinoids: a new class of vasoactive substances.
abstract: Endogenous cannabinoids (endocannabinoids) have recently been identified in the CNS and attention has now turned to their cardiovascular actions. The prototypic endocannabinoid, anandamide, derived from arachidonic acid, has been shown to be a vasorelaxant, particularly in the resistance vasculature. This vasorelaxation has been shown to be both endothelium-independent and -dependent, depending on the vascular bed. It has been proposed that an endocannabinoid may mediate the nitric oxide- and prostanoid-independent component of endothelium-dependent relaxations, as these responses are sensitive to a cannabinoid receptor antagonist and show similarities to anandamide-induced relaxations. This hypothesis has generated much controversy and the emerging conflicts in the literature are discussed in this article by Michael Randall and David Kendall. Despite this controversy, it has recently been shown that anandamide is produced by endothelial cells. Clearly, much work is required to adequately define the physiological significance of endocannabinoids in the cardiovascular system.
authors.affiliation: School of Biomedical Sciences, University of Nottingham Medical School, Queen's Medical Centre, UK.
authors.forename: M D
authors.initials: MD
authors.lastname: Randall
authors.forename: D A
authors.initials: DA
authors.lastname: Kendall
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D001095:Arachidonic Acids / Q000378:metabolism / Q000494:pharmacology*; D001685:Biological Factors / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000378:metabolism / Q000494:pharmacology*; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids / Q000378:metabolism*; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism; D002490:Central Nervous System / Q000378:metabolism*; D063388:Endocannabinoids; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D009569:Nitric Oxide / Q000378:metabolism; D053284:Polyunsaturated Alkamides; D051381:Rats; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000037:antagonists & inhibitors*; D014655:Vascular Resistance / Q000187:drug effects; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D001095:Arachidonic Acids; D001685:Biological Factors; D002121:Calcium Channel Blockers; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D063388:Endocannabinoids; D053284:Polyunsaturated Alkamides; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C067410:endothelium-dependent hyperpolarization factor; D009569:Nitric Oxide; C078814:anandamide